Ireland At Impasse As 'Crunch Meeting' Fails To Unblock New Drug Logjam
Executive Summary
Nine new therapies are stuck in the system in Ireland even though they have been approved for use and the pharmaceutical industry is not convinced by government claims that there is no more cash to fund them.
You may also be interested in...
Delayed Medicines To Hit Irish Market, But Uncertainty Remains For Future
Nine new approved treatments that have faced delays in getting to Irish patients should hit the market this year, says the Health Service Executive. The innovative pharmaceutical industry welcomes the move but is calling for clear political direction on future processes.
Vertex Strikes Novel Reimbursement Deal For Cystic Fibrosis Drugs in Ireland
A novel deal struck by Vertex and the Irish authorities will ensure reimbursement for the company’s cystic fibrosis drugs, Orkambi and Kalydeco, not only for current uses but for newly approved populations – and any new products for the same uses.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.